In a murine model of inflammatory arthritis, the osteoclast specific deletion of FcRIV resulted in a protection from aberrant osteoclast generation and bone erosion in inflamed joints, while inflammation itself was not affected, indicating that inflammatory cytokines alone are not sufficient to induce bone loss in inflammatory arthritis (47). and function. Keywords: rheumatoid factor (RF), autoantibodies against citrullinated proteins (ACPA), osteoclasts, rheumatoid arthritis, cytokines Introduction Skeletal homeostasis is usually managed by continuous removal and replacement of bone throughout life. This process is usually controlled by the coordinated activity of specific bone cells. Osteoclasts are highly specialized multinucleated cells derived from hematopoietic precursors of the myeloid lineage with the capacity to NTRK1 resorb bone [examined in Tanaka et al. (1)]. Osteoclast formation is controlled by the action of soluble mediators, such as receptor activator of nuclear factor-B ligand (RANKL; also known as TNFSF11), macrophage colony-stimulating factor 1 (M-CSF), and unfavorable regulators, such as the decoy receptor for KB-R7943 mesylate RANKL, osteoprotegerin (OPG). These cytokines are provided by cells of the osteoblast lineage and immune cells located within the bone microenvironment [examined in Schett (2)]. Bone resorption also liberates growth factors deposited in bone, which can take action locally on osteoblasts and immune cells. In parallel to osteoclast-mediated bone resorption, bone formation results from the proliferation of skeletal stem cells and their differentiation into osteoblast. Their fate is usually to either stay as bone lining cells or to be embedded into the bone matrix as osteocytes [examined in Bonewald (3)]. The osteoblast cell lineage includes osteoblast precursors, bone lining cells and osteocytes. Each of them express specific signals that regulate resident cells within the bone marrow. In addition to KB-R7943 mesylate the crosstalk between different types of bone cells, there is a tight interaction between bone and immune cells, which is still not fully characterized. The importance of this interaction is usually reflected by diseases, such as rheumatoid arthritis (RA), in which immune activation is linked to bone loss. RA is usually a chronic systemic autoimmune disease affecting about 1% of the population worldwide [examined in McInnes and Schett (4)]. It is associated with pain, joint swelling, progressive disability and systemic comorbidity. One of the major effects of RA is the degradation of cartilage and bone tissue. This process results in joint destruction, which leads to significant loss of life quality for the patients. RA-associated bone loss is characterized by three different manifestations: (i) local erosions in the inflamed joints, where bone and cartilage are in direct contact with the inflamed synovium, (ii) periarticular bone loss of trabecular and cortical bone close to sites of inflammation, and (iii) systemic osteopenia and osteoporosis [examined in Zerbini et al. (5)]. All three forms of bone loss are caused by altered bone homeostasis with increased osteoclast generation and activity resulting in accelerated bone resorption, while osteoblast-mediated bone formation is usually suppressed. The reasons for enhanced osteoclast activity have been in the focus of considerable research. Aside from direct inter-cellular interactions and systemic effects of inflammatory cytokines, autoantibodies have been found to play a major role both via directly influencing osteoclasts, as well as, through the induction of inflammatory cytokines released by macrophages. In this review, we will summarize the current knowledge on autoantibody-mediated bone loss in RA. We will focus on the direct effects of autoantibodies on osteoclasts and pre-osteoclasts as well as indirect effects via cytokines released by activated macrophages. In addition, we will discuss the implications of antibody glycosylation. The Regulation of Osteoclast Activity and Differentiation by Autoantibodies Autoantibodies in RA Although the causes of RA are diverse and not completely understood, it is obvious that disease specific autoantibodies constitute an important trigger. The main autoantibodies associated with RA are the rheumatoid factor (RF) and autoantibodies against citrullinated proteins (ACPA). RF is usually directed against the Fc a part of IgG and mainly occurs as IgM. However, to a smaller extent, RF can also be detected as IgG or IgA. Up to 70% of RA patients are RF positive. Of notice, RF is also found in a subset of healthy people, especially in the elderly, in patients with other rheumatic diseases (e.g., Sj?gren’s syndrome or systemic lupus erythematosus) or in patients with viral infections KB-R7943 mesylate like hepatitis C (6, 7). Although RF is usually positively associated with increased bone erosion, especially KB-R7943 mesylate in ACPA positive patients (8, 9), you will find no data available about its direct effects on cytokine production or osteoclastogenesis. As RF is usually directed against IgG, it might lead to a constant basal inflammation by the formation of.